Cargando…

Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes—A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors

The dermis is the connective layer between the epidermis and subcutis and harbours nerve endings, glands, blood vessels, and hair follicles. The most abundant cell type is the fibroblast. Dermal fibroblasts have a versatile portfolio of functions within the dermis that correspond with different type...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickel, Kimberly, Wensorra, Ursula, Wenck, Horst, Peters, Nils, Genth, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616411/
https://www.ncbi.nlm.nih.gov/pubmed/34831154
http://dx.doi.org/10.3390/cells10112931
_version_ 1784604341756231680
author Nickel, Kimberly
Wensorra, Ursula
Wenck, Horst
Peters, Nils
Genth, Harald
author_facet Nickel, Kimberly
Wensorra, Ursula
Wenck, Horst
Peters, Nils
Genth, Harald
author_sort Nickel, Kimberly
collection PubMed
description The dermis is the connective layer between the epidermis and subcutis and harbours nerve endings, glands, blood vessels, and hair follicles. The most abundant cell type is the fibroblast. Dermal fibroblasts have a versatile portfolio of functions within the dermis that correspond with different types of cells by either direct contact or by autocrine and paracrine signalling. Diabetic skin is characterized by itching, numbness, ulcers, eczema, and other pathophysiological changes. These pathogenic phenotypes have been associated with the effects of the reactive glucose metabolite methylglyoxal (MGO) on dermal cells. In this study, dermal fibroblasts were isolated from diabetic and non-diabetic human donors. Cultured dermal fibroblasts from diabetic donors exhibited reduced insulin-induced glucose uptake and reduced expression of the insulin receptor. This diabetic phenotype persists under cell culture conditions. Secretion of IL-6 was increased in fibroblasts from diabetic donors. Increased secretion of IL-6 and MIF was also observed upon the treatment of dermal fibroblasts with MGO, suggesting that MGO is sufficient for triggering these immunomodulatory responses. Remarkably, MIF treatment resulted in decreased activity of MGO-detoxifying glyoxalase-1. Given that reduced glyoxalase activity results in increased MGO levels, these findings suggested a positive-feedback loop for MGO generation, in which MIF, evoked by MGO, in turn blocks MGO-degrading glyoxalase activity. Finally, secretion of procollagen Type I C-Peptide (PICP), a marker of collagen production, was reduced in fibroblast from diabetic donors. Remarkably, treatment of fibroblasts with either MGO or MIF was sufficient for inducing reduced PICP levels. The observations of this study unravel a signalling network in human dermal fibroblasts with the metabolite MGO being sufficient for inflammation and delayed wound healing, hallmarks of T2D.
format Online
Article
Text
id pubmed-8616411
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86164112021-11-26 Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes—A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors Nickel, Kimberly Wensorra, Ursula Wenck, Horst Peters, Nils Genth, Harald Cells Article The dermis is the connective layer between the epidermis and subcutis and harbours nerve endings, glands, blood vessels, and hair follicles. The most abundant cell type is the fibroblast. Dermal fibroblasts have a versatile portfolio of functions within the dermis that correspond with different types of cells by either direct contact or by autocrine and paracrine signalling. Diabetic skin is characterized by itching, numbness, ulcers, eczema, and other pathophysiological changes. These pathogenic phenotypes have been associated with the effects of the reactive glucose metabolite methylglyoxal (MGO) on dermal cells. In this study, dermal fibroblasts were isolated from diabetic and non-diabetic human donors. Cultured dermal fibroblasts from diabetic donors exhibited reduced insulin-induced glucose uptake and reduced expression of the insulin receptor. This diabetic phenotype persists under cell culture conditions. Secretion of IL-6 was increased in fibroblasts from diabetic donors. Increased secretion of IL-6 and MIF was also observed upon the treatment of dermal fibroblasts with MGO, suggesting that MGO is sufficient for triggering these immunomodulatory responses. Remarkably, MIF treatment resulted in decreased activity of MGO-detoxifying glyoxalase-1. Given that reduced glyoxalase activity results in increased MGO levels, these findings suggested a positive-feedback loop for MGO generation, in which MIF, evoked by MGO, in turn blocks MGO-degrading glyoxalase activity. Finally, secretion of procollagen Type I C-Peptide (PICP), a marker of collagen production, was reduced in fibroblast from diabetic donors. Remarkably, treatment of fibroblasts with either MGO or MIF was sufficient for inducing reduced PICP levels. The observations of this study unravel a signalling network in human dermal fibroblasts with the metabolite MGO being sufficient for inflammation and delayed wound healing, hallmarks of T2D. MDPI 2021-10-28 /pmc/articles/PMC8616411/ /pubmed/34831154 http://dx.doi.org/10.3390/cells10112931 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nickel, Kimberly
Wensorra, Ursula
Wenck, Horst
Peters, Nils
Genth, Harald
Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes—A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors
title Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes—A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors
title_full Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes—A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors
title_fullStr Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes—A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors
title_full_unstemmed Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes—A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors
title_short Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes—A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors
title_sort evaluation of immunomodulatory responses and changed wound healing in type 2 diabetes—a study exploiting dermal fibroblasts from diabetic and non-diabetic human donors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616411/
https://www.ncbi.nlm.nih.gov/pubmed/34831154
http://dx.doi.org/10.3390/cells10112931
work_keys_str_mv AT nickelkimberly evaluationofimmunomodulatoryresponsesandchangedwoundhealingintype2diabetesastudyexploitingdermalfibroblastsfromdiabeticandnondiabetichumandonors
AT wensorraursula evaluationofimmunomodulatoryresponsesandchangedwoundhealingintype2diabetesastudyexploitingdermalfibroblastsfromdiabeticandnondiabetichumandonors
AT wenckhorst evaluationofimmunomodulatoryresponsesandchangedwoundhealingintype2diabetesastudyexploitingdermalfibroblastsfromdiabeticandnondiabetichumandonors
AT petersnils evaluationofimmunomodulatoryresponsesandchangedwoundhealingintype2diabetesastudyexploitingdermalfibroblastsfromdiabeticandnondiabetichumandonors
AT genthharald evaluationofimmunomodulatoryresponsesandchangedwoundhealingintype2diabetesastudyexploitingdermalfibroblastsfromdiabeticandnondiabetichumandonors